HSD17B13

Across TCGA pan-cancer cohorts, HSD17B13 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated HSD17B13 data layer compared with 4 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher HSD17B13 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated HSD17B13 expression acts as an unfavorable survival marker, although some lineages such as MESO and LIHC show a favorable association.

MESO, LIHC, and SKCM are the cancer types where HSD17B13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Quartile	III,IV	0.548	0.242	.003	61	view →
LIHC	OS	Median	All	0.750	0.619	.001	56	view →
SKCM	DFS	Quartile	II,III,IV	0.775	0.603	<.001	47	view →
CESC	DFS	Quartile	II,III,IV	0.688	0.866	.011	36	view →
BLCA	OS	Tertile	III,IV	0.471	0.211	.007	32	view →
LGG	DFS	Median	All	0.653	0.819	<.001	30	view →
UCEC	DFS	Median	All	0.592	0.695	.001	24	view →
LAML	DFS	Quartile	All	0.575	0.296	.011	22	view →
LUAD	OS	Tertile	All	0.854	0.764	.008	20	view →
ACC	DFS	Quartile	II,III,IV	0.441	0.848	.007	19	view →
CHOL	OS	Tertile	II,III,IV	0.223	0.863	.005	16	view →
STAD	DFS	Median	III,IV	0.480	0.731	.009	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

HSD17B13–MESO (DFS)

Open the MESO breakdown →